These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 27514803)
1. Assessing the Biological Activity of the Glucan Phosphatase Laforin. Romá-Mateo C; Raththagala M; Gentry MS; Sanz P Methods Mol Biol; 2016; 1447():107-19. PubMed ID: 27514803 [TBL] [Abstract][Full Text] [Related]
2. Generation and characterization of a laforin nanobody inhibitor. Simmons ZR; Sharma S; Wayne J; Li S; Vander Kooi CW; Gentry MS Clin Biochem; 2021 Jul; 93():80-89. PubMed ID: 33831386 [TBL] [Abstract][Full Text] [Related]
3. A bioassay for Lafora disease and laforin glucan phosphatase activity. Sherwood AR; Johnson MB; Delgado-Escueta AV; Gentry MS Clin Biochem; 2013 Dec; 46(18):1869-76. PubMed ID: 24012855 [TBL] [Abstract][Full Text] [Related]
4. Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy. Chan EM; Ackerley CA; Lohi H; Ianzano L; Cortez MA; Shannon P; Scherer SW; Minassian BA Hum Mol Genet; 2004 Jun; 13(11):1117-29. PubMed ID: 15102711 [TBL] [Abstract][Full Text] [Related]
5. Laforin in autophagy: a possible link between carbohydrate and protein in Lafora disease? Puri R; Ganesh S Autophagy; 2010 Nov; 6(8):1229-31. PubMed ID: 20818153 [TBL] [Abstract][Full Text] [Related]
7. Laforin, a dual specificity phosphatase involved in Lafora disease, is present mainly as monomeric form with full phosphatase activity. Dukhande VV; Rogers DM; Romá-Mateo C; Donderis J; Marina A; Taylor AO; Sanz P; Gentry MS PLoS One; 2011; 6(8):e24040. PubMed ID: 21887368 [TBL] [Abstract][Full Text] [Related]
8. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. Fernández-Sánchez ME; Criado-García O; Heath KE; García-Fojeda B; Medraño-Fernández I; Gomez-Garre P; Sanz P; Serratosa JM; Rodríguez de Córdoba S Hum Mol Genet; 2003 Dec; 12(23):3161-71. PubMed ID: 14532330 [TBL] [Abstract][Full Text] [Related]
9. Lafora disease: Current biology and therapeutic approaches. Mitra S; Gumusgoz E; Minassian BA Rev Neurol (Paris); 2022 Apr; 178(4):315-325. PubMed ID: 34301405 [TBL] [Abstract][Full Text] [Related]
10. Structural mechanism of laforin function in glycogen dephosphorylation and lafora disease. Raththagala M; Brewer MK; Parker MW; Sherwood AR; Wong BK; Hsu S; Bridges TM; Paasch BC; Hellman LM; Husodo S; Meekins DA; Taylor AO; Turner BD; Auger KD; Dukhande VV; Chakravarthy S; Sanz P; Woods VL; Li S; Vander Kooi CW; Gentry MS Mol Cell; 2015 Jan; 57(2):261-72. PubMed ID: 25544560 [TBL] [Abstract][Full Text] [Related]
11. Laforin, a protein with many faces: glucan phosphatase, adapter protein, et alii. Gentry MS; Romá-Mateo C; Sanz P FEBS J; 2013 Jan; 280(2):525-37. PubMed ID: 22364389 [TBL] [Abstract][Full Text] [Related]
12. Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease. Tiberia E; Turnbull J; Wang T; Ruggieri A; Zhao XC; Pencea N; Israelian J; Wang Y; Ackerley CA; Wang P; Liu Y; Minassian BA J Biol Chem; 2012 Jul; 287(30):25650-9. PubMed ID: 22669944 [TBL] [Abstract][Full Text] [Related]
13. The phosphatase activity of laforin is dispensable to rescue Epm2a-/- mice from Lafora disease. Gayarre J; Duran-Trío L; Criado Garcia O; Aguado C; Juana-López L; Crespo I; Knecht E; Bovolenta P; Rodríguez de Córdoba S Brain; 2014 Mar; 137(Pt 3):806-18. PubMed ID: 24430976 [TBL] [Abstract][Full Text] [Related]
14. Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease. Nitschke F; Sullivan MA; Wang P; Zhao X; Chown EE; Perri AM; Israelian L; Juana-López L; Bovolenta P; Rodríguez de Córdoba S; Steup M; Minassian BA EMBO Mol Med; 2017 Jul; 9(7):906-917. PubMed ID: 28536304 [TBL] [Abstract][Full Text] [Related]
15. Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo. Tagliabracci VS; Turnbull J; Wang W; Girard JM; Zhao X; Skurat AV; Delgado-Escueta AV; Minassian BA; Depaoli-Roach AA; Roach PJ Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19262-6. PubMed ID: 18040046 [TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of laforin, a dual-specificity protein phosphatase implicated in Lafora disease. Girard JM; Lê KH; Lederer F Biochimie; 2006 Dec; 88(12):1961-71. PubMed ID: 17010495 [TBL] [Abstract][Full Text] [Related]
17. Mechanistic Insights into Glucan Phosphatase Activity against Polyglucan Substrates. Meekins DA; Raththagala M; Auger KD; Turner BD; Santelia D; Kötting O; Gentry MS; Vander Kooi CW J Biol Chem; 2015 Sep; 290(38):23361-70. PubMed ID: 26231210 [TBL] [Abstract][Full Text] [Related]
18. Glycogenic activity of R6, a protein phosphatase 1 regulatory subunit, is modulated by the laforin-malin complex. Rubio-Villena C; Garcia-Gimeno MA; Sanz P Int J Biochem Cell Biol; 2013 Jul; 45(7):1479-88. PubMed ID: 23624058 [TBL] [Abstract][Full Text] [Related]
19. Laforin, a dual-specificity phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase. Romá-Mateo C; Solaz-Fuster Mdel C; Gimeno-Alcañiz JV; Dukhande VV; Donderis J; Worby CA; Marina A; Criado O; Koller A; Rodriguez De Cordoba S; Gentry MS; Sanz P Biochem J; 2011 Oct; 439(2):265-75. PubMed ID: 21728993 [TBL] [Abstract][Full Text] [Related]